The atypical dopamine transporter inhibitor CE-158 enhances dopamine neurotransmission in the prefrontal cortex of male rats: a behavioral, electrophysiological and microdialysis study.

Altogether, these findings confirm CE-158 as a promising pro-cognitive agent and contribute to assessing its preclinical safety profile in a chronic administration regimen for further translational testing.